Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular AtrophyPRNewsWire • 07/31/23
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business DevelopmentsPRNewsWire • 07/31/23
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate UpdatesPRNewsWire • 07/27/23
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day RunInvestors Business Daily • 06/01/23
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D DayPRNewsWire • 05/31/23
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business DevelopmentsPRNewsWire • 05/12/23
Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory StrategyPRNewsWire • 04/17/23
Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business DevelopmentsPRNewsWire • 03/23/23
Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain DisordersPRNewsWire • 03/22/23
Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual MeetingPRNewsWire • 03/14/23
Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular AtrophyPRNewsWire • 02/21/23
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad CoricInvestors Business Daily • 02/02/23
After Plunging 13% in 4 Weeks, Here's Why the Trend Might Reverse for Biohaven Ltd. (BHVN)Zacks Investment Research • 11/29/22
How Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 54%Zacks Investment Research • 11/28/22